0
Article |

Diagnostic Guidelines for Kawasaki Disease FREE

[+] Author Affiliations

Prepared by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the American Heart Association's Council on Cardiovascular Disease in the Young.

Reproduced with permission; "Diagnostic Guidelines for Kawasaki Disease," 1989; Copyright American Heart Association.

Reprint requests to American Heart Association, 7320 Greenville Ave, Dallas, TX 75231 (Kathryn A. Taubert, PhD)


Am J Dis Child. 1990;144(11):1218-1219. doi:10.1001/archpedi.1990.02150350050022.
Text Size: A A A
Published online

Kawasaki disease, or mucocutaneous lymph node syndrome, is a disease of unknown origin that most frequently (80% of the time) affects infants and children under 5 years of age. Accurate diagnosis and early therapeutic interventions, such as aspirin and intravenous γ-globulin can decrease the approximately 20% risk of developing coronary artery abnormalities. A specific diagnostic test does not exist. Thus, diagnosis of Kawasaki disease is based on characteristic clinical signs and symptoms, which are classified as principal clinical findings and other significant findings. The male-to-female ratio among patients with Kawasaki disease is 1.5:1. Children of nearly all racial backgrounds are affected. Recurrences and cases in siblings are seen only occasionally.

PRINCIPAL CLINICAL FINDINGS  These include fever persisting at least 5 days and the following other principal features: (1) changes in peripheral extremities, including acute, ie, erythema and edema of hands and feet, and convalescent, ie, membranous desquamation of fingertips; (2)

REFERENCES

Hicks RV, Melish ME.  Kawasaki syndrome . Pediatr Clin North Am . 1986;;33:1151-1175.
Newburger JW, Takahashi M, Burns JC, et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin . N Engl J Med . 1986;;315:341-347.
Rowley AH, Gonzalez-Crussi F, Shulman ST.  Kawasaki syndrome . Rev Infect Dis . 1988;;10:1-15.
Rowley AH, Shulman ST.  What is the status of intravenous gamma globulin for Kawasaki syndrome in the United States and Canada? Pediatr Infect Dis J . 1988;;7:463-466.
Shulman ST, ed. Progress in Clinical and Biological Research: Kawasaki Disease . New York, NY: Alan R Liss Inc; 1987;:250.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Hicks RV, Melish ME.  Kawasaki syndrome . Pediatr Clin North Am . 1986;;33:1151-1175.
Newburger JW, Takahashi M, Burns JC, et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin . N Engl J Med . 1986;;315:341-347.
Rowley AH, Gonzalez-Crussi F, Shulman ST.  Kawasaki syndrome . Rev Infect Dis . 1988;;10:1-15.
Rowley AH, Shulman ST.  What is the status of intravenous gamma globulin for Kawasaki syndrome in the United States and Canada? Pediatr Infect Dis J . 1988;;7:463-466.
Shulman ST, ed. Progress in Clinical and Biological Research: Kawasaki Disease . New York, NY: Alan R Liss Inc; 1987;:250.

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.